HomeCompareOSMT vs SBUX

OSMT vs SBUX: Dividend Comparison 2026

OSMT yields 180.18% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OSMT wins by $65.94M in total portfolio value
10 years
OSMT
OSMT
● Live price
180.18%
Share price
$1.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$66.11M
Annual income
$31,604,469.02
Full OSMT calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — OSMT vs SBUX

📍 OSMT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOSMTSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OSMT + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OSMT pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OSMT
Annual income on $10K today (after 15% tax)
$15,315.32/yr
After 10yr DRIP, annual income (after tax)
$26,863,798.67/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, OSMT beats the other by $26,803,332.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OSMT + SBUX for your $10,000?

OSMT: 50%SBUX: 50%
100% SBUX50/50100% OSMT
Portfolio after 10yr
$33.14M
Annual income
$15,837,802.74/yr
Blended yield
47.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

OSMT
Analyst Ratings
5
Buy
Consensus: Buy
Altman Z
-8.0
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OSMT buys
0
SBUX buys
0
No recent congressional trades found for OSMT or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOSMTSBUX
Forward yield180.18%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$66.11M$167.0K
Annual income after 10y$31,604,469.02$71,136.45
Total dividends collected$61.93M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: OSMT vs SBUX ($10,000, DRIP)

YearOSMT PortfolioOSMT Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$28,718$18,018.02$11,121$420.68+$17.6KOSMT
2$79,087$48,359.04$12,548$648.40+$66.5KOSMT
3$209,088$124,464.74$14,440$1,013.98+$194.6KOSMT
4$531,253$307,528.35$17,068$1,617.30+$514.2KOSMT
5$1,298,693$730,252.50$20,912$2,649.52+$1.28MOSMT
6$3,057,980$1,668,378.52$26,875$4,499.29+$3.03MOSMT
7$6,943,500$3,671,461.50$36,771$8,014.12+$6.91MOSMT
8$15,220,649$7,791,104.22$54,542$15,197.11+$15.17MOSMT
9$32,247,458$15,961,362.93$89,602$31,242.49+$32.16MOSMT
10$66,109,249$31,604,469.02$167,011$71,136.45+$65.94MOSMT

OSMT vs SBUX: Complete Analysis 2026

OSMTStock

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Full OSMT Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this OSMT vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OSMT vs SCHDOSMT vs JEPIOSMT vs OOSMT vs KOOSMT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.